Share This:
https://ntp.niehs.nih.gov/go/14635

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 09:43:49

                                                            FINAL #1




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  TEFBINARYMIX

       Lock Date:  03/27/02

       Cage Range:  All

       Reasons For Removal:    25018 Dosing Accident                   25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 002    10 NG / 10 UG
                               Include 003    100 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 007    1000 NG/1000 UG





























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          98           86           98           98           98                        
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                22           19           24           19           20                        
    Natural Death                                      8           12            6           10            7                        
    Dosing Accident                                    1            1            1                         2                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                22           21           22           24           24                        
                                                                                                                                    
  Animals Examined Microscopically                    53           53           53           53           53                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (53)         (53)         (52)         (53)         (52)                      
      Cyst                                                                                                 1 (2%)                   
      Perforation                                                                1 (2%)                    2 (4%)                   
      Muscularis, Inflammation                         3 (6%)       1 (2%)       1 (2%)       3 (6%)       3 (6%)                   
      Periesophageal Tissue, Hemorrhage                                                                    1 (2%)                   
      Periesophageal Tissue, Inflammation                                        1 (2%)                    1 (2%)                   
   Intestine Large, Colon                             (53)         (53)         (53)         (52)         (49)                      
      Hyperplasia, Lymphoid                                                      1 (2%)                                             
      Parasite Metazoan                                             2 (4%)                                                          
   Intestine Large, Rectum                            (53)         (53)         (53)         (53)         (50)                      
      Metaplasia, Squamous                                                                                 1 (2%)                   
      Parasite Metazoan                                2 (4%)                                 1 (2%)       3 (6%)                   
   Intestine Large, Cecum                             (53)         (53)         (53)         (52)         (49)                      
      Mineralization                                                             1 (2%)                                             
   Intestine Small, Jejunum                           (53)         (53)         (52)         (52)         (49)                      
      Hyperplasia, Lymphoid                                                      1 (2%)       2 (4%)       1 (2%)                   
      Ulcer                                                                                   1 (2%)                                
   Intestine Small, Ileum                             (53)         (53)         (52)         (52)         (49)                      
      Hyperplasia, Lymphoid                            1 (2%)                                                                       
   Liver                                              (53)         (53)         (52)         (52)         (51)                      
      Angiectasis                                      3 (6%)       1 (2%)       1 (2%)       2 (4%)       5 (10%)                  
      Basophilic Focus                                 9 (17%)      7 (13%)      8 (15%)      2 (4%)       3 (6%)                   
      Basophilic Focus, Multiple                      13 (25%)     15 (28%)      6 (12%)      1 (2%)       3 (6%)                   
      Cholangiofibrosis                                             1 (2%)                    7 (13%)     39 (76%)                  
      Clear Cell Focus                                 3 (6%)       2 (4%)       2 (4%)       3 (6%)       1 (2%)                   
      Clear Cell Focus, Multiple                       6 (11%)      1 (2%)       1 (2%)                                             
      Eosinophilic Focus                               7 (13%)      8 (15%)      4 (8%)       7 (13%)      1 (2%)                   
      Eosinophilic Focus, Multiple                     7 (13%)      8 (15%)     26 (50%)     33 (63%)     17 (33%)                  
      Fatty Change, Diffuse                            3 (6%)       1 (2%)       9 (17%)     31 (60%)     38 (75%)                  
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
      Fatty Change, Focal                              3 (6%)       4 (8%)       7 (13%)      1 (2%)      12 (24%)                  
      Hematopoietic Cell Proliferation                27 (51%)     29 (55%)     30 (58%)     19 (37%)     11 (22%)                  
      Hepatodiaphragmatic Nodule                                    2 (4%)                                                          
      Hyperplasia, Nodular                                                       2 (4%)      24 (46%)     42 (82%)                  
      Inflammation                                    44 (83%)     41 (77%)     46 (88%)     48 (92%)     46 (90%)                  
      Metaplasia                                                                                           1 (2%)                   
      Mixed Cell Focus                                 7 (13%)      3 (6%)       4 (8%)       2 (4%)       1 (2%)                   
      Mixed Cell Focus, Multiple                      19 (36%)     19 (36%)     26 (50%)     24 (46%)      2 (4%)                   
      Necrosis                                         4 (8%)       8 (15%)      5 (10%)      4 (8%)      20 (39%)                  
      Pigmentation                                     2 (4%)       5 (9%)      38 (73%)     50 (96%)     50 (98%)                  
      Toxic Hepatopathy                                             2 (4%)      34 (65%)     48 (92%)     49 (96%)                  
      Bile Duct, Cyst                                  4 (8%)       3 (6%)       1 (2%)       5 (10%)     23 (45%)                  
      Bile Duct, Dilatation                                         1 (2%)                                                          
      Bile Duct, Fibrosis                              1 (2%)       3 (6%)       3 (6%)       4 (8%)                                
      Bile Duct, Hyperplasia                           8 (15%)      2 (4%)       9 (17%)     29 (56%)     46 (90%)                  
      Centrilobular, Degeneration                      5 (9%)       7 (13%)      2 (4%)       4 (8%)       3 (6%)                   
      Centrilobular, Fibrosis                                                                 1 (2%)       1 (2%)                   
      Hepatocyte, Hypertrophy                          1 (2%)       7 (13%)     17 (33%)     33 (63%)     50 (98%)                  
      Hepatocyte, Multinucleated                                                14 (27%)     46 (88%)     48 (94%)                  
      Oval Cell, Hyperplasia                           2 (4%)       2 (4%)      15 (29%)     39 (75%)     46 (90%)                  
      Portal, Fibrosis                                                                        7 (13%)     34 (67%)                  
      Serosa, Inflammation, Chronic Active             1 (2%)                                                                       
   Mesentery                                          (47)         (47)         (46)         (47)         (42)                      
      Artery, Inflammation, Chronic Active             1 (2%)       1 (2%)       1 (2%)       2 (4%)       4 (10%)                  
      Fat, Necrosis                                                 2 (4%)       2 (4%)       1 (2%)                                
   Oral Mucosa                                        (12)         (11)         (25)         (30)         (36)                      
      Gingival, Hyperplasia, Squamous                  8 (67%)      8 (73%)     18 (72%)     22 (73%)     24 (67%)                  
      Pharyngeal, Inflammation                                                                             1 (3%)                   
   Pancreas                                           (53)         (53)         (52)         (52)         (50)                      
      Inflammation, Chronic Active                                  3 (6%)       3 (6%)       1 (2%)       4 (8%)                   
      Acinus, Atrophy                                               2 (4%)       1 (2%)       1 (2%)       8 (16%)                  
      Acinus, Hyperplasia                              2 (4%)                                 1 (2%)                                
      Acinus, Vacuolization Cytoplasmic                                                       7 (13%)     40 (80%)                  
      Artery, Inflammation, Chronic Active                                       1 (2%)       2 (4%)       2 (4%)                   
      Duct, Dilatation                                                                                     1 (2%)                   
   Salivary Glands                                    (53)         (51)         (52)         (50)         (52)                      
      Inflammation, Chronic Active                                               1 (2%)                                             
   Stomach, Forestomach                               (53)         (53)         (52)         (52)         (51)                      
      Hyperkeratosis                                                             1 (2%)       2 (4%)                                
      Hyperplasia, Squamous                            1 (2%)       1 (2%)       2 (4%)       7 (13%)      8 (16%)                  
      Inflammation                                                               1 (2%)       1 (2%)                                
      Mineralization                                   1 (2%)       1 (2%)                                                          
      Ulcer                                                                      1 (2%)       2 (4%)       1 (2%)                   
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - CONT                                                                                                            
   Stomach, Glandular                                 (53)         (53)         (52)         (52)         (51)                      
      Cyst                                                                                                 1 (2%)                   
      Ectopic Tissue                                                                          1 (2%)                                
      Erosion                                                                                 1 (2%)       2 (4%)                   
      Inflammation, Chronic Active                                               1 (2%)                                             
      Mineralization                                   4 (8%)       3 (6%)       3 (6%)       1 (2%)                                
      Ulcer                                                                      1 (2%)                                             
   Tooth                                              (23)         (14)         (33)         (35)         (31)                      
      Peridontal Tissue, Inflammation                 23 (100%)    14 (100%)    33 (100%)    35 (100%)    31 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                       (53)         (53)         (52)         (53)         (52)                      
      Aorta, Mineralization                                                                   1 (2%)                                
   Heart                                              (53)         (52)         (52)         (53)         (52)                      
      Cardiomyopathy                                  22 (42%)     19 (37%)     22 (42%)     26 (49%)     15 (29%)                  
      Fibrosis                                                                                             1 (2%)                   
      Hemorrhage                                                                                           1 (2%)                   
      Inflammation, Chronic Active                     1 (2%)                                              1 (2%)                   
      Thrombosis                                                                                           1 (2%)                   
      Coronary Artery, Inflammation, Chronic Active                              1 (2%)                    6 (12%)                  
      Pericardium, Necrosis                                                                   1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (53)         (53)         (52)         (52)         (51)                      
      Angiectasis                                     17 (32%)     26 (49%)     33 (63%)     23 (44%)      5 (10%)                  
      Atrophy                                                                                 3 (6%)      35 (69%)                  
      Degeneration, Cystic                            13 (25%)     12 (23%)     13 (25%)     14 (27%)     16 (31%)                  
      Hematopoietic Cell Proliferation                 1 (2%)                                                                       
      Hyperplasia                                     11 (21%)     18 (34%)     23 (44%)     25 (48%)     18 (35%)                  
      Hypertrophy                                     47 (89%)     38 (72%)     44 (85%)     41 (79%)     32 (63%)                  
      Necrosis                                         1 (2%)                                              1 (2%)                   
      Vacuolization Cytoplasmic                       11 (21%)     12 (23%)     14 (27%)     10 (19%)     13 (25%)                  
   Adrenal Medulla                                    (52)         (53)         (52)         (52)         (51)                      
      Hyperplasia                                     15 (29%)     13 (25%)     14 (27%)     13 (25%)      3 (6%)                   
   Islets, Pancreatic                                 (53)         (53)         (52)         (52)         (50)                      
      Hyperplasia                                                                1 (2%)                                             
   Parathyroid Gland                                  (45)         (47)         (46)         (47)         (46)                      
      Hyperplasia                                                   1 (2%)                                                          
   Pituitary Gland                                    (53)         (53)         (53)         (52)         (52)                      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
      Angiectasis                                     17 (32%)     20 (38%)     15 (28%)     17 (33%)      1 (2%)                   
      Cyst                                             1 (2%)       3 (6%)                                                          
      Cytoplasmic Alteration                                                     3 (6%)                                             
      Inflammation                                                                            1 (2%)                                
      Vacuolization Cytoplasmic                                                               1 (2%)                                
      Pars Distalis, Hyperplasia                      13 (25%)     13 (25%)     19 (36%)     20 (38%)     13 (25%)                  
      Pars Intermedia, Hyperplasia                                                                         2 (4%)                   
   Thyroid Gland                                      (53)         (53)         (51)         (52)         (52)                      
      C-Cell, Hyperplasia                             15 (28%)     19 (36%)     22 (43%)     12 (23%)     15 (29%)                  
      Follicle, Cyst                                   2 (4%)                                                                       
      Follicular Cell, Hypertrophy                    14 (26%)     17 (32%)     34 (67%)     35 (67%)     42 (81%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (53)         (53)         (53)         (53)         (50)                      
      Inflammation                                    45 (85%)     49 (92%)     46 (87%)     40 (75%)     23 (46%)                  
      Duct, Cyst                                      38 (72%)     40 (75%)     48 (91%)     43 (81%)     43 (86%)                  
   Ovary                                              (53)         (53)         (52)         (52)         (49)                      
      Atrophy                                         45 (85%)     44 (83%)     45 (87%)     43 (83%)     16 (33%)                  
      Cyst                                            14 (26%)      7 (13%)     17 (33%)     14 (27%)     13 (27%)                  
      Inflammation, Chronic Active                     1 (2%)       1 (2%)                                 1 (2%)                   
      Inflammation, Suppurative                                                               1 (2%)                                
   Oviduct                                            (1)                       (1)          (2)          (3)                       
      Cyst                                             1 (100%)                  1 (100%)     2 (100%)                              
      Inflammation, Chronic Active                                               1 (100%)                  3 (100%)                 
   Uterus                                             (53)         (53)         (53)         (52)         (50)                      
      Adenomyosis                                                                1 (2%)                    1 (2%)                   
      Hemorrhage                                                                                           1 (2%)                   
      Hyperplasia                                                   1 (2%)                                                          
      Inflammation, Chronic Active                     3 (6%)                    1 (2%)       7 (13%)      2 (4%)                   
      Inflammation, Suppurative                        3 (6%)       5 (9%)       8 (15%)     10 (19%)      5 (10%)                  
      Metaplasia, Squamous                            27 (51%)     30 (57%)     35 (66%)     36 (69%)     14 (28%)                  
      Ulcer                                                                                                1 (2%)                   
      Endometrium, Hyperplasia, Cystic                28 (53%)     23 (43%)     34 (64%)     18 (35%)     12 (24%)                  
   Vagina                                             (1)          (1)          (1)          (1)                                    
      Inflammation                                                               1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (53)         (53)         (53)         (53)         (53)                      
      Atrophy                                                       1 (2%)                                                          
      Degeneration                                                               1 (2%)                                             
      Hyperplasia                                     39 (74%)     38 (72%)     42 (79%)     48 (91%)     49 (92%)                  
   Lymph Node                                         (4)          (7)          (2)          (7)          (14)                      
      Angiectasis                                                                             1 (14%)      1 (7%)                   
      Inguinal, Hyperplasia, Plasma Cell                                                      1 (14%)                               
      Lumbar, Ectasia                                  4 (100%)     4 (57%)                   1 (14%)                               
      Lumbar, Hemorrhage                                            2 (29%)                                                         
      Lumbar, Hyperplasia                                           1 (14%)                                                         
      Lumbar, Hyperplasia, Plasma Cell                 4 (100%)     1 (14%)                                                         
      Mediastinal, Ectasia                                                                                 3 (21%)                  
      Mediastinal, Hemorrhage                                                                 1 (14%)      2 (14%)                  
      Mediastinal, Hyperplasia, Histiocytic                         1 (14%)                   1 (14%)      3 (21%)                  
      Mediastinal, Hyperplasia, Lymphoid                            1 (14%)                                                         
      Mediastinal, Hyperplasia, Plasma Cell                                                                2 (14%)                  
      Pancreatic, Hyperplasia, Histiocytic                                                    1 (14%)      3 (21%)                  
      Pancreatic, Hyperplasia, Plasma Cell                                                                 1 (7%)                   
      Pancreatic, Pigmentation                                                                1 (14%)      1 (7%)                   
      Renal, Ectasia                                                1 (14%)      1 (50%)      1 (14%)      1 (7%)                   
      Renal, Hemorrhage                                                          1 (50%)                                            
      Renal, Hyperplasia, Histiocytic                                                         1 (14%)      2 (14%)                  
      Renal, Hyperplasia, Lymphoid                                                                         1 (7%)                   
      Renal, Hyperplasia, Plasma Cell                               1 (14%)                   1 (14%)                               
   Lymph Node, Mandibular                             (53)         (51)         (52)         (50)         (51)                      
      Congestion                                                                              1 (2%)                                
      Ectasia                                                       3 (6%)       6 (12%)      3 (6%)       6 (12%)                  
      Hemorrhage                                                    1 (2%)                                 1 (2%)                   
      Hyperplasia, Lymphoid                            1 (2%)       2 (4%)       3 (6%)       2 (4%)       5 (10%)                  
      Hyperplasia, Plasma Cell                        37 (70%)     37 (73%)     40 (77%)     36 (72%)     31 (61%)                  
   Lymph Node, Mesenteric                             (53)         (53)         (52)         (52)         (49)                      
      Hemorrhage                                                                              1 (2%)                                
      Hyperplasia, Histiocytic                                                                1 (2%)       2 (4%)                   
      Hyperplasia, Lymphoid                                                      1 (2%)                    1 (2%)                   
      Inflammation, Chronic Active                                               1 (2%)                                             
   Spleen                                             (53)         (53)         (52)         (52)         (50)                      
      Fibrosis                                                                                1 (2%)                                
      Hematopoietic Cell Proliferation                51 (96%)     51 (96%)     49 (94%)     47 (90%)     44 (88%)                  
      Hyperplasia                                                                1 (2%)                                             
      Pigmentation                                    47 (89%)     46 (87%)     43 (83%)     51 (98%)     46 (92%)                  
      Lymphoid Follicle, Atrophy                                                 2 (4%)       4 (8%)       5 (10%)                  
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Red Pulp, Atrophy                                1 (2%)                    1 (2%)                    5 (10%)                  
   Thymus                                             (53)         (50)         (48)         (50)         (51)                      
      Atrophy                                         33 (62%)     33 (66%)     43 (90%)     42 (84%)     49 (96%)                  
      Cyst                                                                                    1 (2%)                                
      Hemorrhage                                       1 (2%)                                 3 (6%)       1 (2%)                   
      Hyperplasia, Lymphoid                            2 (4%)                                                                       
      Inflammation                                                                                         1 (2%)                   
      Epithelial Cell, Hyperplasia                                                            1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (53)         (53)         (52)         (53)         (52)                      
      Cyst                                             3 (6%)       2 (4%)       2 (4%)       3 (6%)       1 (2%)                   
      Hyperplasia                                     29 (55%)     29 (55%)     25 (48%)     22 (42%)      3 (6%)                   
      Inflammation, Granulomatous                      5 (9%)                    4 (8%)       3 (6%)                                
      Duct, Cyst                                       1 (2%)                                                                       
   Skin                                               (53)         (53)         (53)         (53)         (53)                      
      Angiectasis                                      1 (2%)                                                                       
      Cyst Epithelial Inclusion                                                               1 (2%)                                
      Fibrosis                                         1 (2%)                                                                       
      Inflammation                                                               1 (2%)                    1 (2%)                   
      Ulcer                                                                      2 (4%)                    1 (2%)                   
      Dermis, Fibrosis                                                           1 (2%)                                             
      Epidermis, Hyperplasia                                                     1 (2%)                                             
      Subcutaneous Tissue, Inflammation                                          1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                    (1)          (1)                       (1)          (1)                       
      Hemorrhage                                                                                           1 (100%)                 
      Inflammation                                                                                         1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (53)         (53)         (53)         (52)         (52)                      
      Hemorrhage                                                                 1 (2%)       1 (2%)                                
      Hydrocephalus                                    1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (53)         (53)         (52)         (53)         (52)                      
      Hemorrhage                                                                 1 (2%)                                             
      Infiltration Cellular, Histiocyte               47 (89%)     41 (77%)     47 (90%)     46 (87%)     45 (87%)                  
      Inflammation                                     8 (15%)      5 (9%)       2 (4%)       4 (8%)       1 (2%)                   
      Metaplasia, Squamous                                                       1 (2%)       2 (4%)      11 (21%)                  
      Mineralization                                                1 (2%)                    1 (2%)                                
      Alveolar Epithelium, Hyperplasia                23 (43%)     20 (38%)     17 (33%)      5 (9%)       5 (10%)                  
      Alveolar Epithelium, Metaplasia, Bronchiolar                  6 (11%)     23 (44%)     34 (64%)     32 (62%)                  
      Bronchiole, Hyperplasia                                                                              1 (2%)                   
      Mediastinum, Hemorrhage                                                                              1 (2%)                   
      Mediastinum, Necrosis                                                                   1 (2%)                                
      Serosa, Inflammation                                                                    1 (2%)                                
   Nose                                               (53)         (53)         (53)         (53)         (53)                      
      Hyperplasia                                                                                          1 (2%)                   
      Inflammation                                    22 (42%)     13 (25%)     13 (25%)     13 (25%)     31 (58%)                  
      Glands, Hyperplasia                                                                                  8 (15%)                  
      Olfactory Epithelium, Degeneration               1 (2%)                                              2 (4%)                   
      Olfactory Epithelium, Metaplasia                 4 (8%)       3 (6%)       5 (9%)       6 (11%)     15 (28%)                  
      Respiratory Epithelium, Hyperplasia             10 (19%)      5 (9%)       7 (13%)     11 (21%)     20 (38%)                  
      Respiratory Epithelium, Metaplasia               1 (2%)                                                                       
      Respiratory Epithelium, Vacuolization                                                                                         
        Cytoplasmic                                                 1 (2%)                                                          
   Trachea                                            (53)         (53)         (52)         (53)         (52)                      
      Inflammation                                     1 (2%)                                                                       
      Peritracheal Tissue, Hemorrhage                                                                      1 (2%)                   
      Peritracheal Tissue, Inflammation                                                                    1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (53)         (53)         (53)         (52)         (52)                      
      Anterior Chamber, Ciliary Body, Cornea,                                                                                       
        Inflammation                                                                          1 (2%)       3 (6%)                   
      Cornea, Inflammation                                                                    1 (2%)                                
      Retina, Atrophy                                  1 (2%)       3 (6%)       4 (8%)       2 (4%)       5 (10%)                  
   Harderian Gland                                    (53)         (53)         (53)         (52)         (52)                      
      Inflammation                                    20 (38%)     14 (26%)     16 (30%)     14 (27%)     16 (31%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (53)         (53)         (52)         (52)         (51)                      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    8                                                              
                                                                                                                                   
NTP Experiment-Test: 96020-01         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04    
Route: GAVAGE                                                                                                     Time: 09:43:49    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       10 NG /      100 NG /     300 NG /     1000 NG/                     
                                                   0 UG         10 UG        100 UG       300 UG       1000 UG                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
URINARY SYSTEM - CONT                                                                                                               
      Accumulation, Hyaline Droplet                    2 (4%)                    1 (2%)       1 (2%)       1 (2%)                   
      Calculus Gross Observation                                    1 (2%)                                                          
      Calculus Micro Observation Only                  7 (13%)      4 (8%)       1 (2%)       4 (8%)       1 (2%)                   
      Casts Protein                                    2 (4%)       1 (2%)                                                          
      Cyst                                                          1 (2%)       1 (2%)       1 (2%)                                
      Infarct                                                                    1 (2%)                    1 (2%)                   
      Inflammation, Chronic Active                     1 (2%)       1 (2%)                    1 (2%)       1 (2%)                   
      Inflammation, Suppurative                        5 (9%)       3 (6%)       1 (2%)       5 (10%)      1 (2%)                   
      Mineralization                                  42 (79%)     38 (72%)     39 (75%)     42 (81%)     35 (69%)                  
      Necrosis                                                                   1 (2%)                                             
      Nephropathy                                     29 (55%)     22 (42%)     29 (56%)     34 (65%)     43 (84%)                  
      Pigmentation                                                  1 (2%)       3 (6%)       7 (13%)     35 (69%)                  
      Pelvis, Dilatation                               1 (2%)                                 2 (4%)       1 (2%)                   
      Pelvis, Inflammation                             3 (6%)                    4 (8%)       3 (6%)       5 (10%)                  
      Renal Tubule, Degeneration                                                 1 (2%)       2 (4%)       1 (2%)                   
      Transitional Epithelium, Hyperplasia             2 (4%)       2 (4%)       4 (8%)      11 (21%)      6 (12%)                  
   Ureter                                             (1)          (1)                       (1)          (1)                       
      Inflammation                                     1 (100%)                               1 (100%)                              
      Mineralization                                                                                       1 (100%)                 
      Transitional Epithelium, Hyperplasia             1 (100%)                                            1 (100%)                 
   Urinary Bladder                                    (53)         (53)         (53)         (52)         (50)                      
      Inflammation                                     7 (13%)      8 (15%)      5 (9%)       7 (13%)                               
      Transitional Epithelium, Hyperplasia                                                    1 (2%)                                
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    9                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------